S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Expands By 73.2%

Thursday, January 14, 2021 | MarketBeat

vTv Therapeutics Inc. (NASDAQ:VTVT) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,810,000 shares, an increase of 73.2% from the December 15th total of 2,200,000 shares. Currently, 29.4% of the shares of the stock are sold short. Based on an average daily volume of 2,700,000 shares, the short-interest ratio is presently 1.4 days.

NASDAQ:VTVT opened at $2.26 on Thursday. The stock's fifty day moving average price is $2.15 and its two-hundred day moving average price is $2.06. vTv Therapeutics has a 52-week low of $1.44 and a 52-week high of $4.75. The company has a market cap of $166.97 million, a price-to-earnings ratio of -5.14 and a beta of -2.00.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.08. The firm had revenue of $0.01 million for the quarter. Analysts forecast that vTv Therapeutics will post -0.4 EPS for the current fiscal year.

In other vTv Therapeutics news, major shareholder Ronald O. Perelman bought 625,000 shares of vTv Therapeutics stock in a transaction dated Thursday, December 10th. The shares were acquired at an average cost of $1.60 per share, with a total value of $1,000,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders bought 1,875,000 shares of company stock worth $3,000,000. Corporate insiders own 1.50% of the company's stock.

A number of large investors have recently bought and sold shares of VTVT. Bank of New York Mellon Corp acquired a new position in shares of vTv Therapeutics in the 2nd quarter valued at $55,000. Jane Street Group LLC acquired a new position in shares of vTv Therapeutics in the 2nd quarter valued at $50,000. Charles Schwab Investment Management Inc. acquired a new position in shares of vTv Therapeutics in the 2nd quarter valued at $48,000. Nuveen Asset Management LLC acquired a new position in shares of vTv Therapeutics in the 2nd quarter valued at $69,000. Finally, Two Sigma Advisers LP lifted its stake in shares of vTv Therapeutics by 332.5% in the 2nd quarter. Two Sigma Advisers LP now owns 163,900 shares of the biotechnology company's stock valued at $369,000 after purchasing an additional 126,000 shares during the period. 5.07% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research downgraded vTv Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, January 9th.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease.

Featured Story: Yield Curve

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Outdoor Recreation Stocks For Growth And Dividends

If American’s liked outdoor activities before, they love them even more now. The COVID-19 pandemic has done many things, and one of them is reinvigorating American’s love of the outdoors. Data from across the industry shows a sustained uptick in revenue that has the entire complex moving higher.

The RV Industry Association, for example, reports shipments of RVs are up greater than 30% in 2020 and are expected to grow another 20% or more in 2021. If data from the two of the industry’s largest manufacturers are any indication, that forecast is very conservative.

And the gains aren’t limited to RVs. Everything that has anything to do with outdoor recreation is booming. Sales at Dicks Sporting Goods, an iconic brand for retail and the outdoors, has seen a sustained 20% increase in revenue since the 2nd quarter shutdowns. If anything, revenue in this sector is being held back by rapidly declining inventory and tight shipping conditions.

The stocks we are about to show all have something in common; the outdoors. Within the group, you will find everything from RVs to Radios and everything in between an outdoor enthusiast could need or want. Some pay dividends and some don’t, but all will deliver solid returns to investors in 2021.

View the "7 Outdoor Recreation Stocks For Growth And Dividends".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.